Merck KGaA upgraded its 2026 earnings and sales guidance driven by strong momentum in Life Science and Healthcare segments despite currency headwinds. The company cited solid demand across its portfol
Merck KGaA reported an earnings decline attributed to negative currency impacts, projecting sales will only match 2025 levels by 2026 at best.
Merck KGaA partners with ChemLex in Singapore to enhance chemical R&D capabilities through automated synthesis, reaction optimization, and high-throughput experimentation.
Merck KGaA launched an HPC platform in partnership with Lenovo and Equinix to enhance research across all company sectors. This infrastructure aims to accelerate innovation within the company's divers
Merck KGaA reported Q3 earnings that beat estimates while tightening guidance, noting organic growth offset negative currency effects.
ChemBrief